NASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis $13.55 +0.54 (+4.15%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$13.25 -0.30 (-2.24%) As of 05:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Amylyx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$13.08▼$13.8650-Day Range$12.74▼$18.3652-Week Range$4.80▼$18.60Volume999,020 shsAverage Volume1.09 million shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/APrice Target$23.00Consensus RatingModerate Buy Company Overview Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options. The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S. Food and Drug Administration approval in 2022 for the treatment of amyotrophic lateral sclerosis (ALS). Amylyx has also filed for regulatory approval of AMX0035 (known as Albrioza) in the European Union and continues to explore its potential utility in other neurodegenerative disorders. In addition to ALS, the Amylyx pipeline includes early-stage programs investigating therapies for Alzheimer’s disease and GM1 gangliosidosis, reflecting the company’s broader commitment to addressing central nervous system pathologies. Amylyx operates primarily in North America and is advancing its global development and commercialization capabilities through strategic collaborations and regulatory engagements. Under the leadership of Chief Executive Officer John H. Johnson III, the company continues to expand clinical development efforts and strengthen its manufacturing and distribution networks. Amylyx’s multidisciplinary team of scientists, clinicians and regulatory experts works to translate preclinical discoveries into potential therapies for patients facing critical neurological challenges.AI Generated. May Contain Errors. Read More Amylyx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreAMLX MarketRank™: Amylyx Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 393rd out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 8 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAmylyx Pharmaceuticals has a consensus price target of $23.00, representing about 69.7% upside from its current price of $13.55.Amount of Analyst CoverageAmylyx Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($1.40) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -9.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -9.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 4.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amylyx Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.10% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 16.33, which indicates bearish sentiment.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently increased by 3.05%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.41 News SentimentAmylyx Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Amylyx Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows4 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.90% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AMLX Stock News HeadlinesAmylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026June 8 at 9:00 AM | businesswire.comPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Amylyx Pharmaceuticals, Inc. – AMLXJune 8 at 8:00 AM | globenewswire.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change. | Porter & Company (Ad)Amylyx Pharmaceuticals Shareholders Approve All Proposals at 2026 Annual MeetingJune 5, 2026 | americanbankingnews.comAmylyx Shareholders Approve Directors, Auditor and Executive PayJune 4, 2026 | tipranks.comA Look At Amylyx Pharmaceuticals (AMLX) Valuation After Its Recent Share Price ReboundJune 2, 2026 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Moderate Buy" by BrokeragesMay 30, 2026 | americanbankingnews.comAmylyx Stock: Why the Full Pipeline Story MattersAmylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares...May 22, 2026 | marketbeat.comSee More Headlines AMLX Stock Analysis - Frequently Asked Questions How have AMLX shares performed this year? Amylyx Pharmaceuticals' stock was trading at $12.08 on January 1st, 2026. Since then, AMLX shares have increased by 12.2% and is now trading at $13.55. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) announced its quarterly earnings data on Thursday, May, 7th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.03. Read the conference call transcript. When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering on Thursday, January 6th 2022. The company issued 10,000,000 shares at a price of $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Top institutional shareholders of Amylyx Pharmaceuticals include Janus Henderson Group PLC (4.48%), First Light Asset Management LLC (2.87%), Bank of America Corp DE (1.20%) and Siren L.L.C. (1.11%). Insiders that own company stock include Joshua B Cohen, Justin B Klee, George M Milne Jr, Patrick D Yeramian, James M Frates, Camille L Bedrosian, Gina Mazzariello, Karen Firestone, Bernhardt G Zeiher and Daphne Quimi. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amylyx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AUO (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/07/2026Today6/10/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/10/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (13m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 AMLX's financial health is in the Green zone, according to TradeSmith. AMLX has been in this zone for over 13 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMLX CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees200Year Founded2013Price Target and Rating Average Price Target for Amylyx Pharmaceuticals$23.00 High Price Target$34.00 Low Price Target$19.00 Potential Upside/Downside+69.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$144.74 million Net MarginsN/A Pretax MarginN/A Return on Equity-55.69% Return on Assets-50.73% Debt Debt-to-Equity RatioN/A Current Ratio17.85 Quick Ratio17.85 Sales & Book Value Annual Sales$87.37 million Price / Sales17.24 Cash FlowN/A Price / Cash FlowN/A Book Value$2.78 per share Price / Book4.87Miscellaneous Outstanding Shares111,190,000Free Float99,067,000Market Cap$1.51 billion OptionableOptionable Beta-0.16 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:AMLX) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
